H.C. Wainwright analyst Andres Y. Maldonado reiterated a Buy rating on Corbus Pharmaceuticals today and set a price target of $40.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Andres Y. Maldonado has given his Buy rating due to a combination of factors that highlight the promising potential of Corbus Pharmaceuticals’ CRB-701. The recent presentation of Phase 1/2 data at ESMO 2025 demonstrated that CRB-701 is a best-in-class antibody-drug conjugate (ADC) for safety and efficacy, showing impressive overall response rates (ORR) across multiple tumor types. The drug’s strong safety profile, with a low incidence of severe adverse events, sets it apart from competitors and supports its broad clinical utility in heavily pretreated solid tumors.
Furthermore, the FDA Fast Track Designations for CRB-701 in specific cancer indications underscore its potential as a near-term value driver for Corbus. The drug’s differentiated safety and efficacy profile, along with its potential for combination therapies, position it well in a competitive market. The enthusiasm from key opinion leaders (KOLs) and the ongoing enrollment in combination trials further enhance the drug’s prospects, making it a compelling asset and a potential acquisition target. These factors collectively reinforce the Buy rating and the $40.00 price target set by Maldonado.
According to TipRanks, Y. Maldonado is a 5-star analyst with an average return of 23.5% and a 53.59% success rate. Y. Maldonado covers the Healthcare sector, focusing on stocks such as Candel Therapeutics, Protara Therapeutics, and Corbus Pharmaceuticals.
In another report released yesterday, LifeSci Capital also maintained a Buy rating on the stock with a $53.00 price target.